Navigation Links
OHSU scientists advance understanding of brain receptor; may help fight neurological disorders
Date:5/28/2013

PORTLAND, Ore. For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

But drug companies have had little success developing clinically effective drugs that target this receptor.

Now, researchers at Oregon Health & Science University's Vollum Institute believe they may understand why. And what they've discovered may help in the development of new therapies for these conditions.

In a paper published in the current issue of the Journal of Neuroscience, OHSU scientists describe their work on NMDA receptors. There are various types of NMDA receptors, resulting from differences in the protein components that make up the receptor. These differences in the protein components produce receptors with varying properties.

As drug companies have worked to develop compounds that manipulate the activity of these receptors, the focus of much of this drug discovery effort has been on a specific NMDA receptor subtype. In their Journal of Neuroscience paper, the OHSU scientists describe their discovery that the specific receptor subtype that drug companies have seen as a target is an almost nonexistent contributor of NMDA receptor action.

What does exist, the OHSU scientists found, was a different kind of NMDA receptor subtype one containing two specific protein components, called GluN2A and GluN2B. NMDA receptors containing these two components were not thought to be very common. The OHSU study found that not only was this NMDA receptor subtype more common than previously believed, it was the most common subtype at synapses. And it was far more common than the receptor subtype that has been the target of drug development efforts.

"What our paper shows is that one reason no drugs have worked well to this point may be because that particular NMDA receptor subtype isn't there in high quantities. The target they've been looking for isn't the target that's there," said Ken Tovar, Ph.D., a senior postdoctoral fellow at the Vollum Institute. Tovar's co-authors on the paper were Gary Westbrook, M.D., senior scientist and co-director of the Vollum Institute, and Matthew McGinley, Ph.D., a former graduate student in the Westbrook laboratory.

Tovar said these findings could provide a new target for drug development.

"If you know what's there, then you know what to go after you just have to figure out how to do it," Tovar said.

The OHSU study also provides clues into how the function of this most common NMDA receptor subtype might be manipulated. Highly specific drugs interact with either GluN2A or GluN2B. Tovar and colleagues demonstrated that when GluN2A and GluN2B coexist in the same receptor, molecules that targeted GluN2A change the behavior of the receptor in ways that could be clinically beneficial.

"NMDA receptors have been implicated in a diverse list of neurological and psychiatric conditions. Thus, the more we know about how to modulate the behavior of the receptors that are there at synapses the greater chance we have of finding drugs to treat these conditions," Tovar said.

"From the perspective of drug development, knowing the nature of your target is one way to keep drug development costs down," said Tovar. "Spending resources investigating a target that turns out to be unimportant means those costs get passed on to the drugs that are effective."


'/>"/>

Contact: Todd Murphy
murphyt@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related biology news :

1. Should I stay or should I go? CSHL scientists link brain cell types to behavior
2. Scientists discover the origin of a giant synapse
3. A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists
4. UCLA life scientists present new insights on climate change and species interactions
5. Scientists sequence genome of sacred lotus, which likely holds anti-aging secrets
6. Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis
7. Salk scientists find potential therapeutic target for Cushings disease
8. American Chemical Society resource connects scientists, discoveries, chemistry & biology interface
9. Scientists alarmed by rapid spread of Brown Streak Disease in cassava
10. Scientists discover how brains auditory center transmits information for decisions, actions
11. Scientists discover new way protein degradation is regulated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2018)... ... November 29, 2018 , ... Tosoh Bioscience LLC ... of acquiring full ownership. The transaction was approved by the Board of Directors ... 2018. “We are extremely pleased to team up with Tosoh Bioscience to offer ...
(Date:11/27/2018)... ... November 26, 2018 , ... uBiome, the leader in microbial ... IBDwatch and Gastroenterology Fellow at the University of Louisville, to its Medical Advisory ... Dr. Wuerth will bring to uBiome knowledge and research on IBD. The appointment ...
(Date:11/27/2018)... THORNTON CLEVELEYS, U.K. (PRWEB) , ... November 27, ... ... polymer to offer the cryogenics industry a sealing solution with a broader range ... (27-29 November) the No-1 PEEK expert will introduce its new VICTREX CT™ 200 ...
Breaking Biology News(10 mins):
(Date:11/9/2018)... ... 08, 2018 , ... IC System, one of the largest ... increasing recovery rates by creating a comprehensive contact strategy for each consumer. ... NLP Logix, a Jacksonville, Florida-based AI solutions company, and leveraged the decades of ...
(Date:11/7/2018)... , ... November 07, 2018 , ... ... been leading a campaign to increase awareness of the adult tissue stem cell ... the month of November, the company is intensifying this effort with new educational ...
(Date:11/6/2018)... and TAHOE, Nev. (PRWEB) , ... November 06, ... ... to their native mobile app for clinical trial data collection and management. ... Now, iPhone users with compatible generation devices can quickly and easily sign in ...
(Date:11/5/2018)... ... 2018 , ... USARAD Holdings Inc., the leading US Joint ... VC firms announces at Distributed Health 2018 conference November 5-6 (Nashville, TN) implementation ... obtaining its first radiology interpretations, one of the first known true use of ...
Breaking Biology Technology: